JP2015533181A5 - - Google Patents

Download PDF

Info

Publication number
JP2015533181A5
JP2015533181A5 JP2015537230A JP2015537230A JP2015533181A5 JP 2015533181 A5 JP2015533181 A5 JP 2015533181A5 JP 2015537230 A JP2015537230 A JP 2015537230A JP 2015537230 A JP2015537230 A JP 2015537230A JP 2015533181 A5 JP2015533181 A5 JP 2015533181A5
Authority
JP
Japan
Prior art keywords
container
typically
powder
chiral
reacted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015537230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/071551 external-priority patent/WO2014060432A1/en
Publication of JP2015533181A publication Critical patent/JP2015533181A/ja
Publication of JP2015533181A5 publication Critical patent/JP2015533181A5/ja
Withdrawn legal-status Critical Current

Links

JP2015537230A 2012-10-16 2013-10-15 Pi3k阻害剤としてのピロロトリアジノン誘導体 Withdrawn JP2015533181A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12382399.9 2012-10-16
EP12382399 2012-10-16
US201261718782P 2012-10-26 2012-10-26
US61/718,782 2012-10-26
PCT/EP2013/071551 WO2014060432A1 (en) 2012-10-16 2013-10-15 Pyrrolotriazinone derivatives as pi3k inhibitors

Publications (2)

Publication Number Publication Date
JP2015533181A JP2015533181A (ja) 2015-11-19
JP2015533181A5 true JP2015533181A5 (https=) 2016-11-10

Family

ID=47049114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015537230A Withdrawn JP2015533181A (ja) 2012-10-16 2013-10-15 Pi3k阻害剤としてのピロロトリアジノン誘導体

Country Status (29)

Country Link
US (1) US9388189B2 (https=)
EP (1) EP2909207A1 (https=)
JP (1) JP2015533181A (https=)
KR (1) KR20150068953A (https=)
CN (1) CN104854108A (https=)
AP (1) AP2015008328A0 (https=)
AR (1) AR093036A1 (https=)
AU (1) AU2013333938A1 (https=)
BR (1) BR112015007231A2 (https=)
CA (1) CA2883426A1 (https=)
CL (1) CL2015000956A1 (https=)
CR (1) CR20150175A (https=)
DO (1) DOP2015000077A (https=)
EA (1) EA027277B1 (https=)
GE (1) GEP201706623B (https=)
GT (1) GT201500094A (https=)
HK (1) HK1211027A1 (https=)
IL (1) IL237475A0 (https=)
MD (1) MD20150048A2 (https=)
MX (1) MX2015004327A (https=)
NI (1) NI201500054A (https=)
PE (1) PE20150637A1 (https=)
PH (1) PH12015500813A1 (https=)
SG (1) SG11201502032VA (https=)
TN (1) TN2015000112A1 (https=)
TW (1) TW201429975A (https=)
UY (1) UY35086A (https=)
WO (1) WO2014060432A1 (https=)
ZA (1) ZA201501220B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
EP2997030B1 (en) * 2013-05-14 2017-08-09 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
MX2017000208A (es) 2014-07-04 2017-05-01 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
CN106467545B (zh) * 2015-08-20 2018-10-16 北大方正集团有限公司 一种噻吩并嘧啶化合物
WO2017076990A1 (en) 2015-11-05 2017-05-11 Almirall, S.A. Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
PL3377495T3 (pl) 2015-11-16 2022-05-16 Topadur Pharma Ag Pochodne 2-fenylo-3,4-dihydropirolo[2,1-f] [1,2,4]triazynonu jako inhibitory fosfodiesterazy i ich zastosowania
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3472165B1 (en) * 2016-06-21 2023-09-06 Nerviano Medical Sciences S.r.l. N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基-吡咯并嘧啶酮化合物及其用途
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3768698B1 (en) 2018-03-19 2025-02-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2022000443A1 (en) * 2020-07-03 2022-01-06 Nanjing Immunophage Biotech Co., Ltd. Methods and compositions for targeting tregs using ccr8 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US6752411B2 (en) 2002-06-24 2004-06-22 Norco Industries, Inc. Multi-stage torsion axle
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
MXPA05011296A (es) 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
SI2612862T1 (sl) * 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
DK200400182U4 (da) 2004-06-23 2005-10-14 Alfa Laval Tank Equipment As Drivenhed især til brug i forbindelse med tankrenseudstyr
GB0417709D0 (en) 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds
AU2006283846B2 (en) * 2005-08-26 2012-04-05 Merck Serono Sa Pyrazine derivatives and use as PI3K inhibitors
US7759350B2 (en) 2005-09-15 2010-07-20 Orchid Research Laboratories Ltd. Pyrimidine carboxamides
US7525866B2 (en) 2006-04-19 2009-04-28 Freescale Semiconductor, Inc. Memory circuit
FI20065449A0 (fi) 2006-06-29 2006-06-29 Nokia Corp Tehonkulutuksen valvontamenetelmä, tehonkulutuksen valvontalaite, tietokoneohjelmatuote, tietokoneohjelman jakeluväline ja kommunikaatioväline
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
ITRN20070034A1 (it) 2007-06-27 2008-12-28 Sica Spa Macchina e metodo di taglio di un tubo estruso in continuo in spezzoni di minore e predeterminata lunghezza.
TWI441601B (zh) 2007-06-28 2014-06-21 Philip Morris Products Sa 具有高白堊含量之圖案化包裝紙
US20100286145A1 (en) 2007-07-26 2010-11-11 Comentis, Inc. Isophthalamide derivatives inhibiting beta-secretase activity
US8658635B2 (en) 2008-06-05 2014-02-25 Glaxosmithkline Intellectual Property Development Limited Benzpyrazol derivatives as inhibitors of PI3 kinases
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
BRPI1014253A2 (pt) 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
WO2011058109A1 (en) * 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
WO2011119704A1 (en) 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists
CA2799579A1 (en) * 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012000202A1 (zh) 2010-07-02 2012-01-05 Tsai Wen-Kai 人员派遣事务机及其应用的人员派遣方法
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
EP2699257A4 (en) 2011-04-21 2014-10-15 Univ Louisiana State PEPTIDE AND CONJUGATE VACCINES FOR FUNGI INFECTIONS
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN102229416B (zh) 2011-06-29 2013-06-05 三一汽车起重机械有限公司 一种起重机闭式回转液压系统及起重机
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods

Similar Documents

Publication Publication Date Title
JP2015533181A5 (https=)
JP2014511840A5 (https=)
RU2019131148A (ru) Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
RU2014102773A (ru) Новые кристаллические формы ингибиторов дипептидилпептидазы-iv
HRP20150273T1 (hr) Spojevi bis(floroalkil)-1,4-benzodiazepinona
GEP20125579B (en) Novel crystalline form vi of agomelatine, preparation method thereof and pharmaceutical compositions containing same
KR102335089B1 (ko) 융합 트리사이클릭 γ-아미노산 유도체, 그 제조방법, 및 그것의 의료 용도
BRPI0913379B8 (pt) intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão
EP4670759A3 (en) Drug delivery device
MX2013009709A (es) Derivados de heteroarilo como moduladores de nachr alfa 7.
WO2012016845A3 (en) Pharmaceutical formulation comprising a phosphodiesterase inhibitor
MX336810B (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos.
HRP20110659T1 (hr) Uporaba beta blokatora za proizvodnju lijeka za liječenje hemangioma
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
MX2015017343A (es) Derivados de pirrolopiridina o pirazolopiridina.
JP2015535831A5 (https=)
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
EP4663637A3 (en) Novel deuterium substituted positron emission tomography (pet) imaging agents and their pharmacological application
MY141306A (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
RU2017142958A (ru) Кристаллы азабициклического соединения
AR075626A1 (es) Metodos para administrar (4ar,10ar)-1-n- propil-1,2,3,4,4a,5,10,10a- octahidro -benzo (g) quinolin-6,7-diol y sus composiciones farmaceuticas. uso.
RU2011145054A (ru) Кристаллические формы саксаглиптина
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
WO2009134531A3 (en) Total synthesis of salinosporamide a and analogs thereof
UA83719C2 (ru) Кристаллическая форма iii агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит